ロード中...
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
BACKGROUND: Determining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to limitations of current disease activity evaluations. OBJECTIVE: Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as an outcom...
保存先:
| 出版年: | J Eur Acad Dermatol Venereol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5034809/ https://ncbi.nlm.nih.gov/pubmed/26201313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.13216 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|